SOLUTIONS
STI Education &
Support
Healthcare providers face a critical challenge: How can they deliver personalized, high-quality care to combat the growing threat of antimicrobial resistance? We have the solution.
Empowering Clinicians,
Improving Care
We equip healthcare providers and patients with the knowledge and tools for effective STI treatment. Our advanced approach ensures accurate diagnosis and personalized treatments, addressing antimicrobial resistance in sexually transmitted infections.
Leading the Way
in STI Testing
We proudly provide the only test in the country that aligns with the latest CDC STI treatment guidelines. This unique capability allows healthcare providers to assess whether patients can be treated with critical antibiotics like Ceftriaxone or Azithromycin, addressing the growing threat of antimicrobial resistance.
Preserving First-Line Treatments: GyrA Testing
for Asymptomatic Cases of Neisseria Gonorrhoeae
Antimicrobial resistance in Neisseria gonorrhoeae is an urgent public health threat 1. Both the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC) report rising resistance to multiple antibiotics, including ceftriaxone—the last widely effective first-line treatment.
Advanced gyrA testing targets genetic markers to determine antibiotic susceptibility or resistance. This allows clinicians to prescribe oral ciprofloxacin for susceptible cases, reducing dependence on ceftriaxone while maintaining effective treatment 2.
By preserving ceftriaxone as a critical treatment option, this approach supports global efforts to combat AMR, safeguard public health, and uphold high standards of patient care.
Approximately 60% of Neisseria gonorrhoeae infections in the U.S. remain susceptible to ciprofloxacin 3
This susceptibility indicates that, when supported by proper antimicrobial resistance testing, ciprofloxacin can still be an effective treatment option for many NG cases. By utilizing molecular tests to confirm ciprofloxacin susceptibility, healthcare providers can confidently prescribe this antibiotic to eligible patients, promoting effective treatment and antibiotic stewardship.
What is Antibiotic stewardship
Antibiotic Stewardship is a smart, targeted approach to making antibiotics work better, longer, and more safely. By ensuring the right antibiotic, stewardship not only improves patient outcomes but also cuts down on unnecessary healthcare costs and fights the rise of resistance. Through ongoing education, evidence-based guidelines, and innovative diagnostic tools, such as rapid molecular resistance tests, stewardship allows for faster, more precise treatment decisions. This approach helps preserve the power of antibiotics, promoting healthier, more sustainable outcomes for everyone.
- Advantages of Targeted Ciprofloxacin Use for NG Infections
Cost-Effectiveness: Ciprofloxacin is generally less expensive than newer alternatives, which can reduce treatment costs.
Availability: Ciprofloxacin is widely available, making it an accessible option for many healthcare providers.
Preservation of Last-Resort Antibiotics: Using ciprofloxacin selectively for susceptible strains helps preserve newer antibiotics, like ceftriaxone, which is essential for treating multidrug-resistant cases of NG.
Reduction in Broad-Spectrum Antibiotic Use: Targeting ciprofloxacin-sensitive cases minimizes the need for broad-spectrum antibiotics, which can contribute to resistance in other bacterial strains.
Patient Comfort and Experience: Oral administration is more comfortable and less invasive, leading to a better overall patient experience.
Tailored Therapy for Mycoplasma Genitalium:
Resistance-Guided Therapy (RGT)
Macrolide resistance in Mycoplasma genitalium poses a significant challenge, driving the need for precise and effective treatment strategies. Two-stage Resistance-Guided Therapy (RGT) approach uses diagnostic testing to detect genetic markers of resistance, enabling personalized antibiotic regimens.
In the first stage, patients receive a seven-day course of doxycycline to reduce the bacterial load. Following this, genetic markers guide the next stage of treatment: azithromycin is prescribed for macrolide-sensitive infections, while moxifloxacin is used for resistant cases 4.
This precision-based method achieves cure rates exceeding 90% while minimizing the unnecessary use of broad-spectrum antibiotics. By reducing the selective pressure for resistance, RGT contributes to long-term antimicrobial stewardship and improved patient outcomes.
Why Resistance-Guided Therapy Matters
Resistance-guided therapy (RGT) plays a vital role in confronting the rising threat of antibiotic resistance. By identifying mutations that cause resistance, RGT empowers healthcare providers to select the most effective treatments tailored to the infection’s resistance profile. This personalized approach significantly increases cure rates to over 90%, particularly for Neisseria gonorrhoeae (NG) and Mycoplasma genitalium (MG) infections, while also reducing treatment failures. RGT preserves essential antibiotics like ceftriaxone and azithromycin for cases that genuinely need them, protecting these critical drugs from overuse.
Beyond improving patient outcomes, RGT benefits public health by lowering STI rates, reducing healthcare costs, and alleviating pressure on healthcare systems. It also promotes awareness among both providers and patients regarding responsible antibiotic use.
Transforming Patient Care
with Resistance Testing
Advanced resistance testing is revolutionizing treatment outcomes by equipping clinicians with the tools to make informed, effective decisions. By integrating molecular diagnostics into everyday practice, we are at the forefront of combating antibiotic-resistant pathogens, ensuring patients receive precise, targeted care. This approach empowers healthcare providers to deliver tailored treatments while safeguarding critical antibiotics, preserving their efficacy to address future challenges.
References:
[1] Centers for Disease Control and Prevention (CDC). (2019) Antibiotic Resistance Threats
[2] Centers for Disease Control and Prevention (CDC). (2021) Gonococcal Infections https://www.cdc.gov/std/treatment-guidelines/gonorrhea-adults.htm
[3] Centers for Disease Control and Prevention (CDC). (2022). Gonococcal Isolate Surveillance Project (GISP) Annual Report 2022 https://www.cdc.gov/sti-statistics/gisp-profiles/index.html
[4] Centers for Disease Control and Prevention (CDC). (2021) Mycoplasma genitalium https://www.cdc.gov/std/treatment-guidelines/mycoplasmagenitalium.htm